Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. Issue 10 (20th October 2020)

• Record Type: Journal Article
• Authors: Ochalek, Jessica; Abbas, Kaja; Claxton, Karl; Jit, Mark; Lomas, James
• Is Part Of: BMJ global health. Volume 5:Issue 10(2020)
• Publication Date: 2020-10-20
• Subjects: health economics -- vaccines; World health -- Periodicals; 362.105
• DOI: 10.1136/bmjgh-2020-003006
• Languages: English
• ISSNs: 2059-7908

Abstract

Abstract : Introduction: Estimating the value of providing effective healthcare interventions in a country requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the resources required had, instead, been made available for other healthcare activities in that country. This potential alternative use of the same resources represents the health opportunity cost of providing the intervention. Without such assessments, there is a danger that blanket recommendations made by international organisations will lead to the adoption of healthcare interventions that are not cost effective in some countries, even given existing donor mechanisms intended to support their affordability. Methods: We assessed the net health impact to 46 Gavi-eligible countries of achieving one of the WHO's proposed 90-70-90 targets for cervical cancer elimination, which includes 90% coverage of human papillomavirus (HPV) vaccination among girls by 15 years of age, using published estimates of the expected additional benefits and costs in each country and estimates of the marginal productivity of each healthcare system. We calculated the maximum price each country could afford to pay for HPV vaccination to be cost effective by assessing the net health impact that would be expected to be generated at different potential prices. Results: At Gavi negotiated prices, HPV vaccination offers net health benefits across most Gavi-eligible countries included in this study. However, if Gavi-eligible countries faced the average price faced by non-Gavi eligible countries, providing HPV vaccination would result in reduced overall population health in most countries. Conclusion: Estimates of the net health impact of providing a healthcare intervention can be used to assess the benefit (or lack of) to countries of adhering to global guidance, inform negotiations with donors, as well as pricing negotiations and the value of developing new healthcare interventions.